Global Single Cell Genomics and Proteomics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Single Cell Genomics and Proteomics Market Size

• The global single cell genomics and proteomics market was valued at USD 4.66 billion in 2024 and is expected to reach USD 14.78 billion by 2032
• During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 15.50%, primarily driven by the rising demand for personalized medicine
• This growth is driven by factors such as the growing prevalence of chronic and infectious disease.

 Single Cell Genomics and Proteomics Market Analysis

• Single cell genomics and proteomics technologies are transformative tools used in advanced biomedical research, allowing scientists to analyze the genetic and proteomic makeup of individual cells
• These tools are essential for understanding cellular heterogeneity, uncovering rare cell populations, and studying complex diseases such as cancer, autoimmune disorders, and neurological conditions at an unprecedented level of detail
• The demand for single cell analysis is significantly driven by the rising focus on personalized medicine, increasing incidence of chronic and infectious diseases, and technological advancements in next-generation sequencing and mass spectrometry
• Research institutions and biopharmaceutical companies are increasingly adopting these tools to gain deeper insights into disease mechanisms and drug responses
• North America stands out as the dominant region in the single cell genomics and proteomics market, owing to its robust healthcare research infrastructure, high R&D investments, and presence of key industry players
  • For instance, the U.S. National Institutes of Health (NIH) has significantly increased funding for single-cell biology projects, and several biotech companies in the U.S. are leading innovation in single-cell platforms, software, and reagents
• Globally, single cell analysis tools are considered among the most valuable technologies in genomics and proteomics labs, following conventional bulk sequencing methods
  They play a pivotal role in advancing precision medicine and developing next-generation therapeutic strategies across oncology, immunology, and stem cell research

Report Scope and Single Cell Genomics and Proteomics Market Segmentation

 Single Cell Genomics and Proteomics Market Trends

“Increasing Adoption of 3D Imaging and Digital Integration”

• One prominent trend in the global single cell genomics and proteomics market is the growing adoption of 3D imaging and digital integration
• These advanced technologies enable researchers to visualize and map cellular structures, gene expression, and protein localization in three dimensions at single-cell resolution 
  • For instance, 3D spatial genomics allows scientists to reconstruct tissue architecture and study how gene activity varies across individual cells in their native environment, which is crucial for understanding tumour microenvironments, neurological diseases, and tissue regeneration 
• Digital integration facilitates real-time data acquisition, automated analysis, and AI-powered visualization tools, streamlining workflows in both research and clinical labs
• This trend is transforming biomedical research by improving data accuracy, enhancing discovery of cell-type-specific biomarkers, and supporting the development of precision medicine applications across oncology, immunology, and neuroscience

Single Cell Genomics and Proteomics Market Dynamics

Driver

“Rising Demand for Precision Medicine and Cellular-Level Insights”

• The growing emphasis on precision medicine and targeted therapies is a key driver of the single cell genomics and proteomics market
• These technologies enable researchers to analyze gene expression and protein activity at the individual cell level, offering deeper insights into complex diseases such as cancer, autoimmune disorders, and neurological conditions
• As biological research shifts toward understanding cellular heterogeneity, single cell analysis becomes essential for identifying rare or disease-driving cell populations
• Advancements in next-generation sequencing (NGS), mass spectrometry, and microfluidics are making these tools more accessible, further propelling market growth
• The ability to obtain high-resolution biological data from individual cells is revolutionizing drug discovery, diagnostics, and personalized treatment approaches

 For instance,

• In August 2023, a report published by Nature Biotechnology revealed that over 40% of all cancer research studies funded in North America now involve single-cell technologies, underscoring their growing role in understanding tumor microenvironments and therapy resistance
• In February 2024, the NIH Common Fund’s Single Cell Analysis Program expanded its funding to support scalable and cost-effective single-cell multi-omics platforms to improve early disease detection and treatment design 
• As a result, single cell genomics and proteomics are becoming vital in bridging the gap between population-level data and individualized therapeutic approaches

Opportunity

“Integration of Artificial Intelligence and Spatial Omics”

• The integration of artificial intelligence (AI) and spatial omics technologies presents a major growth opportunity in the single cell genomics and proteomics market
• AI-driven platforms can analyze massive datasets generated by single-cell experiments, enabling more accurate interpretation, cell-type classification, and biomarker discovery
• Spatial transcriptomics and proteomics add a geographic dimension to single-cell analysis, allowing scientists to study cell-to-cell interactions within tissue architecture

For instance,

• In January 2025, according to Cell Systems Journal, the use of AI in spatial single-cell proteomics improved the ability to detect early-stage neurodegenerative diseases by visualizing protein expression in brain tissue samples
• In November 2023, 10x Genomics and other companies expanded their spatial biology platforms by integrating machine learning tools, allowing researchers to map disease progression with unprecedented clarity 
• These technologies are expected to play a crucial role in personalized immunotherapy, cancer diagnostics, and regenerative medicine, opening doors for both clinical and commercial applications

Restraint/Challenge

“High Costs and Technical Complexity Limiting Widespread Adoption”

• The high cost associated with single cell genomics and proteomics equipment, reagents, and computational tools remains a major barrier to widespread market penetration
•  Platforms for single-cell sequencing or proteomic profiling often require specialized instruments, trained personnel, and complex data analysis pipelines
• Small and mid-sized research institutions, especially in low- and middle-income countries, often face financial constraints in adopting these advanced technologies

For instance,

• In December 2024, according to BioProcess International, single cell RNA-sequencing workflows can cost 5–10 times more than bulk RNA-seq, limiting their use to only high-priority or grant-funded studies  
• These limitations can slow the pace of research and innovation, creating disparities in access and delaying the full potential of precision medicine worldwide

Single Cell Genomics and Proteomics Market Scope

The market is segmented on the basis of single cell genomics process step, Single cell genomics analytical technology, proteomics components, proteomics reagents, proteomics service and software, single cell genomics applications, proteomic application and end user.

 Single Cell Genomics and Proteomics Market Regional Analysis

“North America is the Dominant Region in the Single Cell Genomics and Proteomics Market”

• North America dominates the single cell genomics and proteomics market, fuelled by its strong biotechnology and pharmaceutical sectors, advanced research infrastructure, and substantial funding for precision medicine initiatives
• U.S. holds a major market share owing to the presence of top-tier academic and research institutions, high adoption of next-generation sequencing and mass spectrometry technologies, and a growing number of collaborations between academia and industry
• Increased investment by government agencies such as the NIH and significant support for genomic data analysis platforms contribute to sustained market growth across the region
• In addition, the rising demand for personalized medicine, cancer immunotherapy research, and growing focus on early disease detection are accelerating the adoption of single-cell technologies in both clinical and academic settings

“Asia-Pacific is Projected to Register the Highest Growth Rate”

• Asia-Pacific is expected to experience the fastest growth in the single cell genomics and proteomics market, driven by improving research infrastructure, expanding biotech hubs, and increasing government funding for life sciences
• Countries such as China, India, Japan, and South Korea are becoming key players due to their growing focus on genomic research, large patient populations, and rising interest in precision healthcare
• Japan, known for its innovations in cell and regenerative medicine, continues to invest in high-throughput genomics and proteomics platforms to advance drug development and early disease detection
• China and India are investing heavily in genomic sequencing programs and healthcare innovation, creating a strong pipeline of research in cancer, rare diseases, and immunology. The emergence of local biotechnology start-ups and increased academic-industry partnerships are further propelling regional market expansion

Single Cell Genomics and Proteomics Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Thermo Fisher Scientific Inc.. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• McKesson Corporation (U.S.)
• R1 (U.S.)
• Accenture (Ireland)
• Cognizant (U.S.)
• Siemens (Germany)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bio-Rad Laboratories, Inc. (U.S.)
• BGI (China)
• BD (U.S.)
• Danaher Corporation (U.S.)
• Bruker (U.S.)
• 10x Genomics (U.S.)
• Promega Corporation (U.S.)
• Illumina, Inc. (U.S.)
• QIAGEN (Germany
• Sartorius AG (Germany)

Latest Developments in Global Single Cell Genomics and Proteomics Market

• In January 2025, 10x Genomics launched the Xenium Ranger platform, a high-throughput in situ analysis system for subcellular spatial mapping of gene expression. With enhanced resolution and multiplexing capabilities, it supports research into complex diseases such as cancer and neurodegenerative disorders, advancing discoveries in spatial genomics through scalable insights from intact tissue samples
• In November 2024, Berkeley Lights Inc. introduced the Beacon Ultra platform at the American Society for Cell Biology annual meeting. This single-cell functional proteomics system enables real-time antibody profiling and functional characterization of thousands of individual cells, streamlining biologic drug development and improving candidate selection
• In October 2024, Fluidigm Corporation (now Standard BioTools) unveiled CyTOF XT, a next-generation single-cell mass cytometry instrument, at the Human Cell Atlas conference. It boosts sample throughput and detection sensitivity, supports up to 60 markers, and offers automated workflows for in-depth immune cell phenotyping
• In September 2024, Parse Biosciences launched the EverCode TCR Profiling Kit, designed for high-throughput analysis of T-cell receptor sequences across thousands of single cells. Compatible with EverCode barcoding technology, it aids in immunology, vaccine development, and immune-oncology research. Parse also plans to expand into B-cell receptor and CRISPR screening in early 2025

SKU-50046